Thelansis

  Pro-opiomelanocortin (POMC) deficiency is a form of monogenic obesity resulting in severe early-onset obesity, adrenal insufficiency, red hair and pale skin. POMC deficiency is caused by mutations in the POMC gene, which provides instructions for making the proopiomelanocortin protein. The condition is inherited in an autosomal recessive pattern POMC deficiency is rare; approximately 50 cases have been reported in the medical literature. Thelansis’s “Pro-Opiomelanocortin (POMC) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pro-Opiomelanocortin (POMC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of ...